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Background. Lung cancer is the leading cause of death worldwide. The treatment choice for advanced stage of lung cancer may
depend on histotype, performance status (PS), age, and comorbidities. In the present study, we focused on the effect of metronomic
vinorelbine treatment in elderly patients with advanced unresectable non-small cell lung cancer (NSCLC).Methods. From January
2016 to December 2016, 44 patients affected by non-small cell lung cancer referred to our oncology day hospital were progressively
analyzed. The patients were treated with oral vinorelbine 30 mg x 3/wk or 40 mg x 3/wk meaning one day on and one day off.
The patients were older than 60, stage IIIB or IV, ECOG PS ≥ 1, and have at least one important comorbidity (renal, hepatic,
or cardiovascular disease). The schedule was based on ECOG-PS and comorbidities. The primary endpoint was progression-free
survival (PFS). PFSwas used to compare patients based on different scheduled dosage (30 or 40mg x3/weekly) and age (more or less
than 75 years old) as exploratory analysis. We also evaluated as secondary endpoint toxicity according to Common Toxicity Criteria
Version 2.0. Results. Vinorelbine showed a good safety profile at different doses taken orally and was effective in controlling cancer
progression.Themedian overall survival (OS) was 12 months.The disease control rate (DCR) achieved 63%.Themedian PFS was 9
months. A significant difference in PFS was detected comparing patients aged below with those over 75, and the HR value was 0.72
(p<0.05). Not significant was the difference between groups with different schedules. Conclusions. This study confirmed the safety
profile of metronomic vinorelbine and its applicability for patients unfit for standard chemotherapies and adds the possibility of
considering this type of schedule not only for very elderly patients.
1. Background
Lung cancer is the leading cause of cancer death worldwide.
Tobacco is so far the most important cause of lung cancer,
along with other associated risk factors such as air pollution
and occupational exposure to hazardous chemicals [1]. The
aforementioned could affect the response to chemotherapy
agents [2]. Different histological patterns have changed over
the last 25 years. Indeed, there has been an apparent increase
in adenocarcinoma in both genders [3]. Over the last few
years, advances in systemic treatment of lung cancer have
been made, in particular in non-small cell lung cancer
(NSCLC). However, treatment effectiveness in advanced
stage IIIB or IV non-small cell lung cancer (NSCLC) without
an EGFR-sensitizing mutation or ALK gene rearrangement
has reached a plateau and it could depend on histological
features, performance status (PS), age, and comorbidities.
The recommended therapy in patients with PS 0 to 1
consists of platinum-doublet therapy, whereas in patients
with ECOG-PS 2, combination or single-agent chemotherapy
or palliative care alone is being currently used [4].
The new frontier is the immunotherapy which encom-
passes several molecules that showed to be effective, such
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as nivolumab, atezolizumab, and pembrolizumab, demon-
strating promising effects by allowing the immune cells to
recognize cancer cells but limited bywarnings and side effects
[5].
A high proportion of lung cancer diagnosis occurs in
elderly patients (≥ 65 years), who often represent the most
challenging population to be treated, due to age-related dis-
orders that increase the probability of drug-drug interactions
and treatment-related toxicities [6].
Single-agent chemotherapy (vinorelbine, gemcitabine,
and docetaxel) remains the recommended treatment for
unfit or patient with comorbidities, who are more likely to
develop treatment-related adverse events [3]. An unfit patient
was considered a heterogeneity population based on some
parameters such as stage, ECOG-PS, creatinine level, and
smoking exposition, and they are not considered available for
cisplatin-based chemotherapy [3, 7].
The term “metronomic therapy” refers to the continuous,
often daily, administration of oral chemotherapy agent at
fixed dosage, which aims to reduce toxicity and to prolong
disease control.
Metronomic vinorelbine (mVNR) has been proposed as
a possible alternative therapeutic regimen in patients with
NSCLC [8]. Metronomic chemotherapy is based on the
chronic administration of chemotherapeutic agents at low,
minimally toxic doses and with no drug-free breaks.
Several clinical studies have pointed out the poten-
tial efficacy and low toxicity of metronomic chemother-
apy with potential multitarget properties in cancer patients
[9].
Due to its safety profile, treatment withmetronomic VNR
seems tailored for patients in whom the full-dose treatment
is contraindicated or where the risk-benefit balance is not
favorable, including elderly patients, patients with poor PS,
and patients with important comorbidities [10–12].
The aim of the present study was to evaluate activity and
safety ofmVNR therapy in a sample of patients with advanced
NSCLC stage IIIB or IV, poor performance status (PS≥ 1), and
comorbidities (metabolic renal, hepatic, or cardiovascular
disease). The exploratory analysis was done to compare
different groups of patients according to the schedule of
treatment and the effect of age in terms of progression-free
survival (PFS).
2. Materials and Methods
2.1. Patients. In this study, we retrospectively analyzed 44
patients including elderly (over 60 years at the time of
their NSCLC diagnosis) from our outpatients department
(34 males, 10 females; median age 77 years] suffering from
advanced NSCLC EGFR and ALK wild-type status (IV stage
according to WHO classification system) and who were
assigned to treatment with mVNR.
All patients showed an Eastern Cooperative Oncology
Group ECOG-PS≥1 and at least 1 serious comorbidity such as
metabolic renal, hepatic, and cardiovascular disease. Patients
were either smokers or former smokers. Baseline demo-
graphic data are summarized in Table 1.
Table 1
(a) Baseline study population characteristics [n = 44].
Patients [n] [%]
Gender
Male 34/44 77%
Female 10/44 22%
Median Age [range] 77 [60-90]
Histology
Adenocarcinoma 34/44 77%
Squamous 8/44 18%
unspecified NSCLC 2/44 4%
smoke status
Current smoker 3/44 6%
Former smoker 35/44 79%
never smoker 6/44 13%
ECOG PS: 1 24/44 54%
ECOG PS ≥2 20/44 45%
No. of chemothepy lines
Line I chemotherapy 6/44 13%
Line II chemotherapy 38/44 87%
Response Rate
SD 16/44 36%
PR [partial response] 12/44 27%
PD 16/44 36%
Clinical benefit 28/44 63%
ORR 27% (CI 18-36%)
(b) PFS and OS
PFS mean [months] 9
Overall survival median[months] 12
PFS HR under 75/over 75 years 0.72 <0.05
Thirty-four patients had histological diagnosis of adeno-
carcinoma, eight patients reported squamous cell carcinoma,
and only two cases showed unspecified NSCLC (Table 1).
An ethical committee approval for this study was pro-
vided along with an informed consent through a resolution
number 3382.
2.2. ScheduledmVNRTreatment. Thirty-eight patients received
mVNR treatment after failure of conventional chemotherapy,
while 6 patients received treatment as first-line therapy.
mVNR was administered orally. The therapy was admin-
istered at home and discontinued in presence of serious
toxicity or disease progression.
Patients with ECOG-PS >2 or patients with two or more
comorbidities underwent oral metronomic vinorelbine at 30
mg three times a week, whereas 40 mg three times weekly
was used in patients with ECOG 1 and only one serious
comorbidity.
Patientswere reassessed every 2weekswith clinical exam-
ination, complete blood cell count, and serum chemistry
analysis. Radiologic response was evaluated with a whole
body CT or CT / PET scan every 3 months from the first
administration.
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Table 2: All grade treatment-related toxicities at final analysis [n =
44].
All grade Grade 3/4
Non hematological toxicities
Fatigue 11/44 [25%] 0
Vomiting 2/44 [4%] 0
Diarrhea 5/44 [11%] 0
sensorial Neuropathy 1/44 [2%] 0
Hematological toxicities
Anemia 12/44 [28%] 0
Leukopenia 10/44 [23%] 2/44 [4%]
The primary endpoint was progression-free survival
(PFS), defined as the relapsed time from treatment initiation
to progression disease (PD) or death for any cause.
PFS was also used to compare patients based on different
scheduled dosage (30 or 40 mg x 3/weekly) and age (more or
less than 75 years old).
Toxicities were evaluated according to Common Toxicity
Criteria Version 2.0. We classified adverse events into hema-
tologic including anemia and leukopenia and nonhematolog-
ical events (Table 2).
2.3. Statistical Analysis. All clinical data were assessed as
mean values for continuous variables and as numbers and
percentages for categorical variables. The PFS was analyzed
with Kaplan Meier method; Log rank tests were used to
detect the differences between groups.The statistical analyses
were carried out by using GraphPad (version 5). The statistic
significant value was set at p<0.05.
3. Results
The observational period of our study was 12 months, from
January 2016 to December 2016; the patients under study
underwent metronomic therapy with a high compliance
rate (85%), which is defined as consuming over 75% of the
medication prescribed.
Median age was 77 and the main histotype adenocarci-
noma was present in 77% of all study population.
The smoking status was the following: former smok-
ers 79%, never smokers 13%, and current smokers 6%
(Table 1(a)).
The schedule dosage of mVNR was 40 x 3 a week or 30 x
3 depending on ECOG-PS.
Patients with PS 2 were 18, whereas 26 patients had PS
1. Patients aged >75 were 31, whereas 13 were patients aged
between 60 and 75. Vinorelbine was used as first-line in only
6 patients, whereas 38 patients were treated as second line.
After 3 months of mVNR therapy, none of the patients
showed a complete response; 12/44 patients (27.3%) showed
a partial response as their objective response rate (ORR)
with a CI from 18 to 36% (Table 1(a)). 16/44 (36%) of
patients had a stable disease.The clinical benefit considered as
disease control rate (DCR) was observed in 63% of patients.
Progression disease was observed in 16/44 patients (36%).
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Figure 1: Kaplan Meier curve on global progression-free survival.
Overall, 15/44 patients achieved 12 months of observational
time.
The mean PFS was 9 months (Figure 1, Table 1(b)) and
median overall survival (OS) 12 months. No statistically
significant results were found comparing the two types of
schedule (30 versus 40mg x 3/weekly) with aHR 1.1 (Figure 2).
Conversely, a statistically significant difference, in terms of
PFS, was found referring to age (more or less than 75 years
old) with HR 0.72 (p=0.006) (Figure 3, Table 1(b)).
Furthermore, our results demonstrated that single-agent
vinorelbine administered three times a week was well tol-
erated and only 4% of the patients experienced grade 3
adverse reactions (neutropenia), thereby requiring granulo-
cyte colony-stimulating factor administration.Thenonhema-
tological side effects included fatigue 25%, vomiting 4%, and
diarrhea 11% (Table 2). No toxic deaths events occurred.
4. Discussion
Our data suggest safety profile of metronomic oral vinorel-
bine irrespective of schedule dosage. Thirty and 40mgs three
times a week were effective in the same way in terms of
response rate.
Nevertheless, a difference regarding PFS was found in
subgroups depending on age. In fact, the major benefit was
observed in patients younger than 75yrs.
The disease control rate of 63% and the ORR suggest us to
consider single-agent chemotherapy at metronomic schedule
in patients affected by several comorbidities having a low
ECOG- PS. We can use a low dosage since the clinical benefit
was reached at both doses, 30 mg x 3/wk and 40 mg x 3/wk.
The OS, the ORR, and the mean PFS observed in our
patients suggest that vinorelbine is effective in such subgroups
of patients and that tumor cell growth was slowed by just one
agent especially in elderly patients.
Several could be the targets of the aforementioned.
mVNR efficacy seems to be related to the activity in tumor
angiogenesis, being active on endothelial cells growth, on
circulating tumor cells, and on endothelial progenitor cells in
the bone marrow [13].
Although studies onmetronomic treatment are restricted
and have not been definitively accepted, several clinical trials
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Figure 2: Kaplan Meier curve comparing the two types of schedule [30x3 versus 40x3 mgs/weekly].
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Figure 3: Kaplan Meier curve in function of age.
have reported that metronomic is a well-tolerated treatment.
Moreover, the real impact of metronomic chemotherapy on
carcinogenesis and metastasis has not yet been clarified,
as well as its potential as a sensitizer for radiotherapy. Its
demonstrated therapeutic effects on tumor growth and its
low toxicity allow us to consider this option in consolidation
approaches in specific subsets of patients. Few data have
also been reported on the effect of metronomic treatment
in patients younger than 75yrs as we showed in the current
study.
Chemotherapy resistance and failure are usually related to
a group of tumor-initiating cancer stem cells (CSCs) involved
in drug resistance, metastasis, and relapse of cancers. The
use of chemotherapy at low doses alludes to the hypoth-
esis that chemotherapeutical agents may act on different
cell targets. Several lines of evidence indicate a significant
antiangiogenetic activity together with a potential impact
on the immune system [14, 15]. In addition, metronomic
treatment seems to be able to prevent therapy-induced
stromal activation with consequent activation of tumor-
initiating cells in human desmoplastic cancers and orthotopic
tumor xenografts [16]. Moreover, metronomic treatments
may minimize the chemotherapy-host response that may
counteract beneficial antitumor response [14].
Several studies point out that mVNR appears to show
comparable effectswith other chemotherapeutic agents, espe-
cially in elderly patients with a good safety profile [17].
Intravenously or orally administered vinorelbine
demonstrated the same metabolism pattern, with identical
pharmacokinetic-pharmacodynamics behaviour and it is
able to maintain clinical efficacy as well [18].
In a randomized study carried out on elderly patients,
oral vinorelbine administration (60 mg/m2) was compared
to intravenous paclitaxel (90 mg/m2), where no significant
differences in clinical benefit were observed [19].
Due to its safety profile [20],mVNR seems to be a suitable
treatment also for patients in whom the full-dose treatment is
contraindicated or when the risk-benefit balance is unfavor-
able, including not only elderly patients, but also subjectswith
poor PS and patients with important comorbidities [10–12].
In a Phase II study with mVNR administered three times
a week in 43 naive patients, including unfit patients with a
median age of 80 yrs, ECOG>2, ORR 18.6%, amedian time to
progression (TTP) of 5months, and amedian OS of 9months
were reported [21].
This study, as well as others based on a mathematical
model, revealed that oral mVNR in elderly patients showed
long-term disease stabilization and optimal patient compli-
ance in elderly patients [22–25]. Furthermore, several lines of
evidence demonstrated that vinorelbine improves survival in
elderly patients and quality of life (QoL) [26]. Therefore, oral
vinorelbine represents an appropriate agent for the treatment
of selected elderly patients because of its good safety profile.
Vinorelbine could have multiple sites and mechanisms
of action including the antiangiogenic properties and more
recently an impact on the tumor microenvironment has been
proposed as a potential effect involving the immune system
[27]. We have to consider its multifunctionality since a large
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quantity of studies demonstrated that doublet chemotherapy
as second-line therapy in elderly patients is more toxic and
does not improve overall survival compared to single-agent
[28].
A future application of vinorelbine may be considered
in combination with other treatments, such as immunother-
apy, since preclinical studies showed that vinorelbine could
sensitize patients to immunotherapy through a synergistic
action with PDL-1 receptors [29]. The use of single-agent in
anticancer therapy along with best supportive care has often
to be considered [30].
As a consequence, currentlywe should direct the choice of
treatment according to the clinical evaluation of the patient,
therefore tailoring the therapy.
Weknow from the literature thatmathematicalmodelling
may allow physicians to choose the treatment’s regimen
which encompasses the timing of administration, based on
the evaluation of tolerability and pharmacokinetics [31].
Recent new trials reported that pharmacokinetics of the
aforementioned vinorelbine is stable and the toxicity is
associated with high dose of the drug [32]. Another recent
prospective trial explored the activity and feasibility ofmVNR
30 mg x 3/wk in selected groups of elderly patients, with
advanced disease and poor prognosis owing to the presence
of distant metastases and comorbidities. The trial reported
a disease control rate of roughly 30%, higher in first-line
treatment than in second-line with a PFS better in the first-
line group [33].
Eventually, a potential synergism of action was demon-
strated in combination with anti-EGFR in studies in vitro
using lung cancer cell lines such as A 549, H-292. mVNR
showed to be also effective in resistant cell clones by
decreasing the expression of cyclin D1 and inhibiting the
phosphorylation of AKT and ERK 1 which are proteins
involved in cell proliferation[34].
5. Conclusion
Metronomic therapy appears to be an interesting area for
the treatment of a specific subset of patients with low
PS and comorbidities. Our data support this hypothesis.
Moreover, they confirmed the good safety and activity profile
of metronomic treatment irrespective of schedule dosage.
Our results suggest that patients younger than 75yrs have
a better response than older ones, underling the possible
application of this treatment not only in very elderly patients,
recommending the lowest schedule dose at 30mg x 3/wks in
presence of significant comorbidities.
Therefore, metronomic oral vinorelbine could be the
choice treatment for elderly patients unfit for traditional
cisplatin-based chemotherapy, both in first- and second-line
treatments because it is safe and well tolerated and is less
expensive than other standard chemotherapies and more
effective than best supportive care alone. It is important to
take into account the fact that anticancer therapy is not able
to totally eradicate cancer cells. The possible new paradigm
for cancer therapy, in patients where full recovery from the
disease is not possible, may be to reduce tumor burden over
time. Indeed, our data are in line with this observation.
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